The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors
Vinayak Palve, Claire E. Knezevic, Daniel S. Bejan, Yunting Luo, Xueli Li, Silvia Novakova, Eric A. Welsh, Bin Fang, Fumi Kinose, Eric B. Haura, Álvaro N.A. Monteiro, John M. Koomen, Michael S. Cohen, Harshani R. Lawrence, Uwe Rix
Topics & Concepts
OlaparibPARP1Wee1Poly ADP ribose polymeraseCancer researchGene silencingBiologyPARP inhibitorPhosphoproteomicsSynthetic lethalityDNA damageDNA repairCell cycleCancerCell biologyCyclin-dependent kinase 1PolymeraseGeneticsDNAPhosphorylationProtein phosphorylationGeneProtein kinase APARP inhibition in cancer therapyAdvancements in Semiconductor Devices and Circuit DesignSemiconductor materials and devices